NCT03793660 (BINAR) is a clinical trial in Arthritis, Rheumatoid, sponsored by Dacima Consulting.

Who is sponsoring NCT03793660?

NCT03793660 is sponsored by Dacima Consulting.

What condition does NCT03793660 study?

NCT03793660 studies Arthritis, Rheumatoid, Spondylitis.

Is NCT03793660 still recruiting?

NCT03793660 is currently completed. Last updated 22 August 2022.

Last reviewed 2022-08-22 · How we verify

NCT03793660: BINAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biologic National Registry

Completed Last updated 22 August 2022

What this trial tests

trial in Arthritis, Rheumatoid in 439 participants. Completed in 30 June 2022.

Timeline

23 May 2018

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	Dacima Consulting
Status	Completed
Study type	OBSERVATIONAL
Enrollment	439
Start date	23 May 2018
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	10 locations across Tunisia

Conditions studied

Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →
Spondylitis — all drugs for Spondylitis →

Sponsor

Dacima Consulting

Who can join

18 and older, any sex, with Arthritis, Rheumatoid or Spondylitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BINAR is an open and multicentric Tunisian national registry performed by nearly 100 rheumatologists

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Arthritis, Rheumatoid

Currently open trials in the same condition.

NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting

Other Dacima Consulting trials

Trials by the same sponsor.

NCT07034274 — National Tunisian Clinical Registry on CardioVascular Secondary Prevention Clinical · recruiting
NCT06934499 — Tunisian Lung Cancer Study · recruiting
NCT06825533 — The Prevalence of Prediabetes in Primary Care Medicine in Tunisia · not yet recruiting
NCT06445036 — Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism · not yet recruiting
NCT05991089 — Tunisian Clinical Registry on Chronic Kidney Disease in Hypertensive Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03793660 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dacima Consulting
Last refreshed: 22 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03793660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing